Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 182
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
J Gene Med ; 23(11): e3379, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34296780

RESUMEN

BACKGROUND: Osteoarthritis (OA) is a degenerative disease characterized by cartilage damage. We aimed to improve the understanding of the protective mechanism of synovial mesenchymal stem cell (SMSC)-derived extracellular vesicles (EVs) in cartilage damage of OA. METHODS: SMSCs and SMSC-EVs were isolated from synovial biopsies of patients without OA and then identified. The pathological microenvironment of chondrocytes in OA was simulated by inducing SW1353 cells with interleukin (IL)-1ß, followed by SMSC-EV treatment to assess SW1353 cell proliferation, apoptosis and inflammation. Endocytosis of Dil-labeled EVs by SW1353 cells was observed. microRNA (miR)-26a-5p expression in EVs and EV-treated SW1353 cells was assessed. The effect of miR-26a-5p was evaluated after it was down-regulated in SMSCs, followed by extraction of EVs, which acted on SW1353 cells. The target relationship of miR-26a-5p and phosphatase and tensin homologue (PTEN) was predicted and confirmed. The role of PTEN in OA was evaluated after it was overexpressed. Functional assays were implemented in vivo to certify the role of SMSC-EVs in OA. RESULTS: SMSC-EVs enhanced IL-1ß-induced SW1353 cell proliferation, whereas they inhibited apoptosis and inflammation. EVs were endocytosed by SW1353 cells and delivered miR-26a-5p into SW1353 cells to overexpress miR-26a-5p. Down-regulation of miR-26a-5p in EVs attenuated the protection of EVs against IL-1ß-induced cell damage. miR-26a-5p targeted PTEN, for which overexpression spoiled the protection of EVs against IL-1ß-induced cell damage. SMSC-EVs carrying miR-26a-5p repaired cartilage damage of OA. CONCLUSIONS: SMSC-EVs carried miR-26a-5p into chondrocytes to up-regulate miR-26a-5p and inhibit PTEN, thereby inhibiting apoptosis and inflammation and ameliorating cartilage damage of OA.


Asunto(s)
Vesículas Extracelulares/metabolismo , Células Madre Mesenquimatosas/metabolismo , MicroARNs/metabolismo , Osteoartritis/metabolismo , Fosfohidrolasa PTEN/metabolismo , Membrana Sinovial/metabolismo , Adulto , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/metabolismo , Línea Celular Tumoral , Proliferación Celular , Células Cultivadas , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Interleucina-1beta/metabolismo , Masculino , MicroARNs/genética , Osteoartritis/genética , Fosfohidrolasa PTEN/genética
2.
Biochem Biophys Res Commun ; 529(2): 210-217, 2020 08 20.
Artículo en Inglés | MEDLINE | ID: mdl-32703413

RESUMEN

Developmental dysplasia of the hip (DDH) is a common hip disease characterized by abnormal development of the acetabulum and femoral head. In most cases, DDH ultimately leads to osteoarthritis. Anomalous biomechanical force plays an important role in cartilage degeneration in DDH. However, in addition to mechanical wear, the underlying molecular mechanisms in cartilage degeneration in DDH remain unclear. This study analyzed the effect of long noncoding RNA (lncRNA)-H19 on DDH cartilage degradation. To elucidate the specific role of lncRNA H19, we established an intermittent cyclic mechanical stress (ICMS) cell force model to simulate abnormal biomechanical environment in vitro. Then, the roles of lncRNA-H19 were also determined in vivo by establishing a model of swaddling DDH. We observed that patients with DDH possessed low levels of lncRNA-H19, COL2A1, and Aggrecan but high levels of MMP3 and Adamts5. The same results were also obtained in a DDH rat model. Furthermore, the data suggested that ICMS promoted cartilage degeneration and caused reorientation of the cytoskeleton, and lncRNA H19 helped inhibit cartilage degeneration. Bioinformatics analysis and lncRNA sequencing were performed, and luciferase assays showed that lncRNA H19 and Dusp5 are both direct targets of miR-483-5p. Moreover, Dups5 plays a negative role in ICMS-induced cartilage degradation by activating the Erk and p38 pathways. In vivo, lncRNA H19 had protective effects on the swaddling DDH model. These findings indicate that lncRNA-H19 played a positive role in cartilage degradation in DDH through the lncRNA H19/miR-483-5p/Dusp5 axis.


Asunto(s)
Enfermedades de los Cartílagos/genética , Displasia del Desarrollo de la Cadera/genética , Fosfatasas de Especificidad Dual/genética , MicroARNs/genética , ARN Largo no Codificante/genética , Animales , Enfermedades de los Cartílagos/etiología , Enfermedades de los Cartílagos/patología , Células Cultivadas , Displasia del Desarrollo de la Cadera/complicaciones , Displasia del Desarrollo de la Cadera/patología , Regulación de la Expresión Génica , Ratas
3.
Osteoarthritis Cartilage ; 27(11): 1636-1646, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31299386

RESUMEN

OBJECTIVE: WNT signaling is of key importance in chondrogenesis and defective WNT signaling may contribute to the pathogenesis of osteoarthritis and other cartilage diseases. Biochemical composition of articular cartilage in patients with aberrant WNT signaling has not been studied. Our objective was to assess the knee articular cartilage in WNT1 mutation-positive individuals using a 3.0T MRI unit to measure cartilage thickness, relaxation times, and texture features. DESIGN: Cohort comprised mutation-positive (N = 13; age 17-76 years) and mutation-negative (N = 13; 16-77 years) subjects from two Finnish families with autosomal dominant WNT1 osteoporosis due to a heterozygous missense mutation c.652T>G (p.C218G) in WNT1. All subjects were imaged with a 3.0T MRI unit and assessed for cartilage thickness, T2 and T1ρ relaxation times, and T2 texture features contrast, dissimilarity and homogeneity of T2 relaxation time maps in six regions of interest (ROIs) in the tibiofemoral cartilage. RESULTS: All three texture features showed opposing trends with age between the groups in the medial tibiofemoral cartilage (P = 0.020-0.085 for the difference of the regression coefficients), the mutation-positive individuals showing signs of cartilage preservation. No significant differences were observed in the lateral tibiofemoral cartilage. Cartilage thickness and means of T2 relaxation time did not differ between groups. Means of T1ρ relaxation time were significantly different in one ROI but the regression analysis displayed no differences. CONCLUSIONS: Our results show less age-related cartilage deterioration in the WNT1 mutation-positive than the mutation-negative subjects. This suggests, that the WNT1 mutation may alter cartilage turnover and even have a potential cartilage-preserving effect.


Asunto(s)
Enfermedades de los Cartílagos/genética , Cartílago Articular/metabolismo , Imagen por Resonancia Magnética/métodos , Mutación , Vía de Señalización Wnt/genética , Proteína Wnt1/genética , Adolescente , Adulto , Anciano , Enfermedades de los Cartílagos/metabolismo , Enfermedades de los Cartílagos/patología , Cartílago Articular/patología , ADN/genética , Análisis Mutacional de ADN , Femenino , Humanos , Articulación de la Rodilla/metabolismo , Articulación de la Rodilla/patología , Masculino , Persona de Mediana Edad , Proteína Wnt1/metabolismo , Adulto Joven
4.
Rheumatol Int ; 39(4): 751-755, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30612148

RESUMEN

Idiopathic hip chondrolysis is a rare disorder, the pathophysiology of which has not been fully elucidated. Several theories have been proposed regarding the cause of the disease with some of them involving autoimmune-mediated cartilage destruction. There are several similar features between idiopathic hip chondrolysis and rheumatologic diseases such as juvenile idiopathic arthritis, so whether these two disorders are different or not is still debatable. This case report aims to help comprehending this complex disorder by presenting a case of idiopathic hip chondrolysis with apparent risk factors, such as repetitive microtrauma and presence of HLA-B27 antigens. A 15-year-old HLA-B27 positive male presented with idiopathic hip chondrolysis after excessive walking. Initial treatment consisted of medications including corticosteroids, protected weight bearing and surgical soft tissue release. After failure of all these modalities in restoring the decreased range of motion of the hip, a course of a TNF-inhibitor, etanercept was tried. Alleviation of pain achieved early in the treatment period, but range of motion remained mainly unchanged. Although there was a brief improvement of stiffness for a short period after surgery which lasted for about 3 months, stiffness came back afterwards. Administration of a TNF inhibitor in the following period significantly improved his range of motion. The presence of laboratory findings indicating an autoimmune tendency in this patient supports the hypothesis of susceptibility of these patients to autoimmune reactions, while excessive walking was an apparent trigger factor. In future, traditional treatments may be abandoned in favor of novel medications targeting immunologic pathways.


Asunto(s)
Enfermedades de los Cartílagos/diagnóstico por imagen , Cartílago Articular/diagnóstico por imagen , Articulación de la Cadera/diagnóstico por imagen , Refugiados , Caminata , Adolescente , Artritis Juvenil/diagnóstico , Artroscopía , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/patología , Enfermedades de los Cartílagos/terapia , Cartílago Articular/patología , Diagnóstico Diferencial , Etanercept/uso terapéutico , Antígeno HLA-B27/genética , Articulación de la Cadera/cirugía , Humanos , Imagen por Resonancia Magnética , Masculino , Modalidades de Fisioterapia , Radiografía , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Población Blanca
5.
Vet Pathol ; 56(6): 895-902, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31526126

RESUMEN

Chondrodystrophy results in predictable and progressive biochemical and structural changes to the intervertebral disc, resulting in early onset degeneration and dystrophic mineralization of the disc. Accelerated degeneration and mineralization of the intervertebral disc are common in multiple dog breeds and can result in compromised function, herniation, pain, and a variety of neurological sequelae. A mutation responsible for chondrodystrophy in dogs has been identified as an aberrant fibroblast growth factor 4 (FGF4) retrogene insertion on chromosome 12 (CFA12) and is associated with short stature of the Nova Scotia Duck Tolling Retriever. Segregation of the CFA12 FGF4 retrogene in this dog breed provides an opportunity to examine the effect of retrogene presence on radiographic and histologic appearance of chondrodystrophic disc degeneration within a single breed. Here we found that in the intervertebral discs isolated from 2 dogs with the CFA12 FGF4 genotype, the nucleus pulposus was largely replaced by cartilaginous tissue, and physaliferous notochordal cells were rarely if ever identified. These findings are in contrast to the normal histologic findings in 2 breed-matched dogs lacking the mutation. The findings are consistent with premature chondroid degeneration of the intervertebral disc and suggest that the presence of the CFA12 FGF4 retrogene is sufficient to cause the chondrodystrophic phenotype.


Asunto(s)
Enfermedades de los Cartílagos/veterinaria , Enfermedades de los Perros/patología , Factor 4 de Crecimiento de Fibroblastos/genética , Degeneración del Disco Intervertebral/veterinaria , Animales , Enfermedades de los Cartílagos/diagnóstico , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/patología , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/genética , Perros , Genotipo , Disco Intervertebral/patología , Degeneración del Disco Intervertebral/diagnóstico , Degeneración del Disco Intervertebral/genética , Degeneración del Disco Intervertebral/patología , Fenotipo
6.
Blood ; 127(15): 1847-55, 2016 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-26758921

RESUMEN

Vitamin K-dependent coagulation factors deficiency is a bleeding disorder mainly associated with mutations in γ-glutamyl carboxylase (GGCX) that often has fatal outcomes. Some patients with nonbleeding syndromes linked to GGCX mutations, however, show no coagulation abnormalities. The correlation between GGCX genotypes and their clinical phenotypes has been previously unknown. Here we report the identification and characterization of novel GGCX mutations in a patient with both severe cerebral bleeding disorder and comorbid Keutel syndrome, a nonbleeding malady caused by functional defects of matrix γ-carboxyglutamate protein (MGP). To characterize GGCX mutants in a cellular milieu, we established a cell-based assay by stably expressing 2 reporter proteins (a chimeric coagulation factor and MGP) in HEK293 cells. The endogenous GGCX gene in these cells was knocked out by CRISPR-Cas9-mediated genome editing. Our results show that, compared with wild-type GGCX, the patient's GGCX D153G mutant significantly decreased coagulation factor carboxylation and abolished MGP carboxylation at the physiological concentration of vitamin K. Higher vitamin K concentrations can restore up to 60% of coagulation factor carboxylation but do not ameliorate MGP carboxylation. These results are consistent with the clinical results obtained from the patient treated with vitamin K, suggesting that the D153G alteration in GGCX is the causative mutation for both the bleeding and nonbleeding disorders in our patient. These findings provide the first evidence of a GGCX mutation resulting in 2 distinct clinical phenotypes; the established cell-based assay provides a powerful tool for studying the clinical consequences of naturally occurring GGCX mutations in vivo.


Asunto(s)
Ligasas de Carbono-Carbono/genética , Mutación , Sangrado por Deficiencia de Vitamina K/genética , Anomalías Múltiples/genética , Secuencia de Aminoácidos , Secuencia de Bases , Pruebas de Coagulación Sanguínea , Sistemas CRISPR-Cas , Calcinosis/genética , Proteínas de Unión al Calcio/genética , Enfermedades de los Cartílagos/genética , Análisis Mutacional de ADN , Proteínas de la Matriz Extracelular/genética , Femenino , Genes Reporteros , Estudios de Asociación Genética , Genotipo , Células HEK293 , Deformidades Congénitas de la Mano/genética , Hemorragia , Humanos , Lactante , Recién Nacido , Datos de Secuencia Molecular , Fenotipo , Estenosis de la Válvula Pulmonar/genética , Homología de Secuencia de Aminoácido , Homología de Secuencia de Ácido Nucleico , Proteína Gla de la Matriz
7.
Adv Exp Med Biol ; 1059: 331-350, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29736581

RESUMEN

Osteochondral (OC) lesions are a major cause of chronic musculoskeletal pain and functional disability, which reduces the quality of life of the patients and entails high costs to the society. Currently, there are no effective treatments, so in vitro and in vivo disease models are critically important to obtain knowledge about the causes and to develop effective treatments for OC injuries. In vitro models are essential to clarify the causes of the disease and the subsequent design of the first barrier to test potential therapeutics. On the other hand, in vivo models are anatomically more similar to humans allowing to reproduce the pattern and progression of the lesion in a controlled scene and offering the opportunity to study the symptoms and responses to new treatments. Moreover, in vivo models are the most suitable preclinical model, being a fundamental and a mandatory step to ensure the successful transfer to clinical trials. Both in vitro and in vitro models have a number of advantages and limitation, and the choice of the most appropriate model for each study depends on many factors, such as the purpose of the study, handling or the ease to obtain, and cost, among others. In this chapter, we present the main in vitro and in vivo OC disease models that have been used over the years in the study of origin, progress, and treatment approaches of OC defects.


Asunto(s)
Enfermedades Óseas , Enfermedades de los Cartílagos , Modelos Animales , Animales , Animales Modificados Genéticamente , Enfermedades Óseas/etiología , Enfermedades Óseas/genética , Enfermedades Óseas/terapia , Enfermedades de los Cartílagos/inducido químicamente , Enfermedades de los Cartílagos/etiología , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/terapia , Técnicas de Cultivo de Célula , Condrocitos/citología , Condrogénesis , Técnicas de Cocultivo , Modelos Animales de Enfermedad , Humanos , Traumatismos de la Rodilla/etiología , Mamíferos , Técnicas de Cultivo de Órganos , Osteoartritis/etiología , Osteoartritis/genética , Osteoartritis/patología , Osteoartritis/terapia , Osteogénesis , Ingeniería de Tejidos/métodos , Andamios del Tejido
8.
Curr Osteoporos Rep ; 15(4): 255-270, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28585220

RESUMEN

PURPOSE OF REVIEW: We give an update on the etiology and potential treatment options of rare inherited monogenic disorders associated with arterial calcification and calcific cardiac valve disease. RECENT FINDINGS: Genetic studies of rare inherited syndromes have identified key regulators of ectopic calcification. Based on the pathogenic principles causing the diseases, these can be classified into three groups: (1) disorders of an increased extracellular inorganic phosphate/inorganic pyrophosphate ratio (generalized arterial calcification of infancy, pseudoxanthoma elasticum, arterial calcification and distal joint calcification, progeria, idiopathic basal ganglia calcification, and hyperphosphatemic familial tumoral calcinosis; (2) interferonopathies (Singleton-Merten syndrome); and (3) others, including Keutel syndrome and Gaucher disease type IIIC. Although some of the identified causative mechanisms are not easy to target for treatment, it has become clear that a disturbed serum phosphate/pyrophosphate ratio is a major force triggering arterial and cardiac valve calcification. Further studies will focus on targeting the phosphate/pyrophosphate ratio to effectively prevent and treat these calcific disease phenotypes.


Asunto(s)
Calcificación Vascular/genética , Anomalías Múltiples/tratamiento farmacológico , Anomalías Múltiples/genética , Anomalías Múltiples/metabolismo , Enfermedades de la Aorta/tratamiento farmacológico , Enfermedades de la Aorta/genética , Enfermedades de la Aorta/metabolismo , Enfermedades de los Ganglios Basales/tratamiento farmacológico , Enfermedades de los Ganglios Basales/genética , Enfermedades de los Ganglios Basales/metabolismo , Calcinosis/tratamiento farmacológico , Calcinosis/genética , Calcinosis/metabolismo , Enfermedades de los Cartílagos/tratamiento farmacológico , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/metabolismo , Hipoplasia del Esmalte Dental/tratamiento farmacológico , Hipoplasia del Esmalte Dental/genética , Hipoplasia del Esmalte Dental/metabolismo , Difosfatos/metabolismo , Terapia de Reemplazo Enzimático , Enfermedad de Gaucher/tratamiento farmacológico , Enfermedad de Gaucher/genética , Enfermedad de Gaucher/metabolismo , Deformidades Congénitas de la Mano/tratamiento farmacológico , Deformidades Congénitas de la Mano/genética , Deformidades Congénitas de la Mano/metabolismo , Humanos , Hiperostosis Cortical Congénita/tratamiento farmacológico , Hiperostosis Cortical Congénita/genética , Hiperostosis Cortical Congénita/metabolismo , Hiperfosfatemia/tratamiento farmacológico , Hiperfosfatemia/genética , Hiperfosfatemia/metabolismo , Interferones/metabolismo , Metacarpo/anomalías , Metacarpo/metabolismo , Enfermedades Musculares/tratamiento farmacológico , Enfermedades Musculares/genética , Enfermedades Musculares/metabolismo , Odontodisplasia/tratamiento farmacológico , Odontodisplasia/genética , Odontodisplasia/metabolismo , Osteoporosis/tratamiento farmacológico , Osteoporosis/genética , Osteoporosis/metabolismo , Fosfatos/metabolismo , Progeria/tratamiento farmacológico , Progeria/genética , Progeria/metabolismo , Seudoxantoma Elástico/tratamiento farmacológico
9.
IUBMB Life ; 68(9): 756-63, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27521280

RESUMEN

Cartilage engineering is one challenging issue in regenerative medicine. Low oxygen tension or hypoxia inducible factor-1 (HIF-1α) gene therapy are promising strategies in the field of cartilage repair. Previously, we showed that hypoxia and its mediator HIF-1 regulate matrix genes expression (collagens and aggrecan). Here, we investigated the molecular mechanism involved in the regulation of type I collagen (COL1A1) by HIF-1 in human articular chondrocytes. We show that HIF-1α reduces COL1A1 transcription, through a distal promoter (-2300 to -1816 bp upstream transcription initiation site), containing two GC boxes that bind Sp transcription factors (Sp1/Sp3). Sp1 acts as a positive regulator but is not induced by HIF-1. COL1A1 inhibition caused by HIF-1 implies only Sp3, which accumulates and competes Sp1 binding on COL1A1 promoter. Additionally, Sp3 ectopic expression inhibits COL1A1, while Sp3 knockdown counteracts the downregulation of COL1A1 induced by HIF-1. In conclusion, we established a new regulatory model of COL1A1 regulation by HIF-1, and bring out its relationship with Sp3 transcription factor. In a fundamental level, these findings give insights in the mechanisms controlling COL1A1 gene expression. This may be helpful to improve strategies to impair type I collagen expression during chondrocyte differentiation for cartilage engineering. © 2016 IUBMB Life, 68(9):756-763, 2016.


Asunto(s)
Enfermedades de los Cartílagos/genética , Colágeno Tipo I/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Factor de Transcripción Sp3/genética , Enfermedades de los Cartílagos/patología , Enfermedades de los Cartílagos/terapia , Diferenciación Celular/genética , Condrocitos/metabolismo , Condrocitos/patología , Colágeno Tipo I/biosíntesis , Cadena alfa 1 del Colágeno Tipo I , Regulación del Desarrollo de la Expresión Génica , Terapia Genética , Humanos , Regiones Promotoras Genéticas , Factor de Transcripción Sp3/metabolismo
10.
Genet Couns ; 26(2): 187-94, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26349188

RESUMEN

Keutel syndrome (KS) is an autosomal recessive disease characterised by abnormal cartilage calcification, brachytelephalangism, peripheral pulmonary artery stenosis, hearing loss and midface retrusion. KS is caused by homozygous mutations in MGP, a gene encoding Matrix Gla protein which acts as a calcification inhibitor in extracellular matrix. We present two Turkish sisters (22 and 13 years old) who had abnormal cartilage calcification, brachytelephalangism, congenital heart defect and chronic asthmatic bronchitis. The patients were homozygous for c.62-2A>G (IVS1-2 A>G) mutation in MGP gene. Abnormal cartilage calcification, brachytelephalangism and midfacial retrusion are the hallmarks of KS. It was observed that the younger sister had striking cartilaginous calcifications, midfacial retrusion and severe brachytelephalangism while her older sister had mild costal cartilaginous calcifications and brachytelephalangism without any midfacial retrusion. Intrafamiliar clinical variability for KS has not been described previously.


Asunto(s)
Anomalías Múltiples/genética , Anomalías Múltiples/patología , Calcinosis/genética , Calcinosis/patología , Proteínas de Unión al Calcio/genética , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/patología , Proteínas de la Matriz Extracelular/genética , Deformidades Congénitas de la Mano/genética , Deformidades Congénitas de la Mano/patología , Estenosis de la Válvula Pulmonar/genética , Estenosis de la Válvula Pulmonar/patología , Adolescente , Adulto , Femenino , Homocigoto , Humanos , Mutación , Hermanos , Adulto Joven , Proteína Gla de la Matriz
11.
Acta Orthop ; 86(1): 92-9, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25175665

RESUMEN

BACKGROUND AND PURPOSE: We reviewed the current state of research on microRNAs in age-related diseases in cartilage and bone. METHODS: PubMed searches were conducted using separate terms to retrieve articles on (1) the role of microRNAs on aging and tissue degeneration, (2) specific microRNAs that influence cellular and organism senescence, (3) microRNAs in age-related musculoskeletal conditions, and (4) the diagnostic and therapeutic potential of microRNAs in age-related musculoskeletal conditions. RESULTS: An increasing number of studies have identified microRNAs associated with cellular aging and tissue degeneration. Specifically in regard to frailty, microRNAs have been found to influence the onset and course of age-related musculoskeletal conditions such as osteoporosis, osteoarthritis, and posttraumatic arthritis. Both intracellular and extracellular microRNAs may be suitable to function as diagnostic biomarkers. INTERPRETATION: The research data currently available suggest that microRNAs play an important role in orchestrating age-related processes and conditions of the musculoskeletal system. Further research may help to improve our understanding of the complexity of these processes at the cellular and extracellular level. The option to develop microRNA biomarkers and novel therapeutic agents for the degenerating diseases of bone and cartilage appears to be promising.


Asunto(s)
Envejecimiento/genética , Enfermedades de los Cartílagos/genética , Senescencia Celular/genética , MicroARNs/fisiología , Osteoartritis/genética , Osteoporosis/genética , Enfermedades Óseas/genética , Humanos
12.
Usp Fiziol Nauk ; 46(4): 90-6, 2015.
Artículo en Ruso | MEDLINE | ID: mdl-27183786

RESUMEN

In the review the literary data on studying of biological role of a oligomerny matriksny of protein of the cartilage in exchange processes connecting tissue at people and animals are provided, and also results of own researches on definition of a oligomerny matriksny of protein of the cartilage as a modern marker of a metabolism of an articulate cartilage at children from undifferentiated displaziy conjunctive tissue are briefly described.


Asunto(s)
Enfermedades de los Cartílagos/metabolismo , Proteína de la Matriz Oligomérica del Cartílago/metabolismo , Cartílago/metabolismo , Animales , Cartílago/patología , Enfermedades de los Cartílagos/genética , Proteína de la Matriz Oligomérica del Cartílago/genética , Niño , Humanos
13.
Toxicol Appl Pharmacol ; 274(2): 339-49, 2014 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-24262764

RESUMEN

One of the major challenges when testing drug candidates targeted at a specific pathway in whole animals is the discrimination between specific effects and unwanted, off-target effects. Here we used the zebrafish to define several developmental defects caused by impairment of Egf signaling, a major pathway of interest in tumor biology. We inactivated Egf signaling by genetically blocking Egf expression or using specific inhibitors of the Egf receptor function. We show that the combined occurrence of defects in cartilage formation, disturbance of blood flow in the trunk and a decrease of myelin basic protein expression represent good indicators for impairment of Egf signaling. Finally, we present a classification of known tyrosine kinase inhibitors according to their specificity for the Egf pathway. In conclusion, we show that developmental indicators can help to discriminate between specific effects on the target pathway from off-target effects in molecularly targeted drug screening experiments in whole animal systems.


Asunto(s)
Factor de Crecimiento Epidérmico/antagonistas & inhibidores , Receptores ErbB/antagonistas & inhibidores , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Transducción de Señal , Pez Cebra/genética , Animales , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Enfermedades de los Cartílagos/genética , Factor de Crecimiento Epidérmico/genética , Factor de Crecimiento Epidérmico/metabolismo , Receptores ErbB/genética , Receptores ErbB/metabolismo , Vaina de Mielina/genética , Vaina de Mielina/metabolismo , Inhibidores de Proteínas Quinasas/toxicidad , Choque/genética , Tirfostinos/toxicidad , Pez Cebra/metabolismo
14.
Am J Med Genet A ; 164A(4): 1062-8, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24458983

RESUMEN

Keutel syndrome is a rare, autosomal recessive disorder characterized by diffuse cartilage calcification, peripheral pulmonary artery stenosis, midface retrusion, and short distal phalanges. To date, 28 patients from 18 families have been reported, and five mutations in the matrix Gla protein gene (MGP) have been identified. The matrix Gla protein (MGP) is a vitamin K-dependent extracellular protein that functions as a calcification inhibitor through incompletely understood mechanisms. We present the clinical manifestations of three affected siblings from a consanguineous Turkish family, in whom we detected the sixth MGP mutation (c.79G>T, which predicts p.E27X) and a fourth unrelated patient in whom we detected the seventh MGP mutation, a partial deletion of exon 4. Both mutations predict complete loss of MGP function. One of the patients presented initially with a working diagnosis of relapsing polychondritis. Clinical features suggestive of Keutel syndrome were also observed in one additional unrelated patient who was later found to have a deletion of arylsulfatase E, consistent with a diagnosis of X-linked recessive chondrodysplasia punctata. Through a discussion of these cases, we highlight the clinical overlap of Keutel syndrome, X-linked chondrodysplasia punctata, and the inflammatory disease relapsing polychondritis.


Asunto(s)
Anomalías Múltiples/genética , Arilsulfatasas/genética , Calcinosis/genética , Proteínas de Unión al Calcio/genética , Enfermedades de los Cartílagos/genética , Condrodisplasia Punctata/genética , Proteínas de la Matriz Extracelular/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Deformidades Congénitas de la Mano/genética , Policondritis Recurrente/genética , Estenosis de la Válvula Pulmonar/genética , Eliminación de Secuencia , Adulto , Exones , Femenino , Humanos , Masculino , Adulto Joven , Proteína Gla de la Matriz
15.
Am J Med Genet A ; 164A(11): 2849-56, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25123378

RESUMEN

Keutel syndrome (KS) [OMIM 245150] is an autosomal recessive hereditary syndrome characterized by multiple peripheral pulmonary stenoses (PPS), brachytelephalangia, inner ear deafness, and abnormal cartilage ossification or calcification. Mutations in the matrix Gla protein (MGP) gene have been reported in different unrelated families with KS previously. MGP is an extracellular matrix protein and calcification inhibitor; mutations in its encoding gene result in cartilage ossification or calcification, the main presenting feature of KS. This report describes the findings of four sisters with KS born to consanguineous parents were followed for 26 years in an irregular fashion. During follow-up of the patients over the years the complications appear to be mostly involving the respiratory system. Permanent skin rashes, papillary microcarcinoma of the thyroid, asthma, massive bullous pulmonary emphysema, severe systemic arterial hypertension, and short term memory loss were observed during long term follow-up. The fertility status of the patients were also observed and infertility was observed in one of three married patients.


Asunto(s)
Anomalías Múltiples/diagnóstico , Anomalías Múltiples/genética , Calcinosis/diagnóstico , Calcinosis/genética , Enfermedades de los Cartílagos/diagnóstico , Enfermedades de los Cartílagos/genética , Deformidades Congénitas de la Mano/diagnóstico , Deformidades Congénitas de la Mano/genética , Fenotipo , Estenosis de la Válvula Pulmonar/diagnóstico , Estenosis de la Válvula Pulmonar/genética , Adulto , Biopsia , Consanguinidad , Facies , Femenino , Estudios de Seguimiento , Humanos , Pulmón/patología , Factores de Riesgo , Hermanos , Piel/patología , Glándula Tiroides/diagnóstico por imagen , Glándula Tiroides/patología , Tomografía Computarizada por Rayos X , Adulto Joven
16.
Connect Tissue Res ; 55(4): 257-61, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24844414

RESUMEN

The Hedgehog (Hh) family of proteins consists of Indian hedgehog (Ihh), sonic hedgehog (Shh), and desert hedgehog (Dhh). These proteins serve as essential regulators in a variety of developmental events. Ihh is mainly produced and secreted by prehypertrophic chondrocytes and regulates chondrocyte hypertrophy and endochondral bone formation during growth plate development. Tissue-specific deletion of the Ihh gene (targeted by Col2a1-Cre) causes early lethality in mice. Transgenic mice with induced Ihh expression exhibit increased chondrocyte hypertrophy and cartilage damage resembling human osteoarthritis (OA). During OA development, chondrocytes recapitulate the differentiation process that happens during the fetal status and which does not occur to an appreciable degree in adult articular cartilage. Ihh expression is up-regulated in human OA cartilage, and this upregulation correlates with OA progression and changes in chondrocyte morphology. A genetic study in mice further showed that conditional deletion of Ihh in chondrocytes attenuates OA progression, suggesting the possibility that blocking Ihh signaling can be used as a therapeutic approach to prevent or delay cartilage degeneration. However, Ihh gene deletion is currently not a therapeutic option as it is lethal in animals. RNA interference (RNAi) provides a means to knockdown Ihh without the severe side effects caused by chemical inhibitors. The currently available delivery methods for RNAi are nanoparticles and liposomes. Both have problems that need to be addressed. In the future, it will be necessary to develop a safe and effective RNAi delivery system to target Ihh signaling for preventing and treating OA.


Asunto(s)
Enfermedades de los Cartílagos/metabolismo , Cartílago/metabolismo , Condrocitos/metabolismo , Proteínas Hedgehog/metabolismo , Osteoartritis/metabolismo , Adulto , Animales , Cartílago/patología , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/patología , Enfermedades de los Cartílagos/terapia , Condrocitos/patología , Técnicas de Silenciamiento del Gen , Proteínas Hedgehog/genética , Humanos , Ratones , Ratones Transgénicos , Nanopartículas , Osteoartritis/genética , Osteoartritis/patología , Osteoartritis/terapia , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/uso terapéutico
17.
Arthritis Rheum ; 65(8): 2090-101, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23658108

RESUMEN

OBJECTIVE: Meniscus tears are associated with a heightened risk of osteoarthritis. This study aimed to advance our understanding of the metabolic state of injured human meniscus at the time of arthroscopic partial meniscectomy through transcriptome-wide analysis of gene expression in relation to the patient's age and degree of cartilage chondrosis. METHODS: The degree of chondrosis of knee cartilage was recorded at the time of meniscectomy in symptomatic patients without radiographic osteoarthritis. RNA preparations from resected menisci (n = 12) were subjected to transcriptome-wide microarray and QuantiGene Plex analyses. Variations in the relative changes in gene expression with age and chondrosis were analyzed, and integrated biologic processes were investigated computationally. RESULTS: We identified a set of genes in torn menisci that were differentially expressed with age and chondrosis. There were 866 genes that were differentially regulated (≥1.5-fold difference and P < 0.05) with age and 49 with chondrosis. In older patients, genes associated with cartilage and skeletal development and extracellular matrix synthesis were repressed, while those involved in immune response, inflammation, cell cycle, and cellular proliferation were stimulated. With chondrosis, genes representing cell catabolism (cAMP catabolic process) and tissue and endothelial cell development were repressed, and those involved in T cell differentiation and apoptosis were elevated. CONCLUSION: Differences in age-related gene expression suggest that in older adults, meniscal cells might dedifferentiate and initiate a proliferative phenotype. Conversely, meniscal cells in younger patients appear to respond to injury, but they maintain the differentiated phenotype. Definitive molecular signatures identified in damaged meniscus could be segregated largely with age and, to a lesser extent, with chondrosis.


Asunto(s)
Envejecimiento , Regulación de la Expresión Génica , Traumatismos de la Rodilla/genética , Análisis por Matrices de Proteínas/métodos , Lesiones de Menisco Tibial , Adolescente , Adulto , Factores de Edad , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/metabolismo , Enfermedades de los Cartílagos/patología , Cartílago Articular/metabolismo , Cartílago Articular/patología , Desdiferenciación Celular/genética , Perfilación de la Expresión Génica , Humanos , Traumatismos de la Rodilla/metabolismo , Traumatismos de la Rodilla/patología , Laceraciones , Meniscos Tibiales/metabolismo , Meniscos Tibiales/patología , Persona de Mediana Edad
18.
Curr Osteoporos Rep ; 12(4): 439-45, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25212565

RESUMEN

Growth plate is a specialized cartilaginous structure that mediates the longitudinal growth of skeletal bones. It consists of ordered zones of chondrocytes that secrete an extracellular matrix (ECM) composed of specific types of collagens and proteoglycans. Several heritable human skeletal dysplasias are caused by mutations in these ECM components and this review focuses on the roles of type II, IX, X, and XI collagens, aggrecan, matrilins, perlecan, and cartilage oligomeric matrix protein in the growth plate as deduced from human disease phenotypes and mouse models. Substantial advances have been achieved in deciphering the interaction networks and individual roles of these components in the construction of the growth plate ECM. Furthermore, ER stress and other cellular responses have been identified as key downstream effects of the ECM mutations contributing to abnormal growth plate development. The next challenge is to utilize the molecular level knowledge for the development of potential therapeutics.


Asunto(s)
Condrocitos/fisiología , Proteínas de la Matriz Extracelular/fisiología , Placa de Crecimiento/crecimiento & desarrollo , Placa de Crecimiento/fisiología , Animales , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/patología , Enfermedades de los Cartílagos/fisiopatología , Proliferación Celular/fisiología , Condrocitos/citología , Modelos Animales de Enfermedad , Estrés del Retículo Endoplásmico/fisiología , Proteínas de la Matriz Extracelular/genética , Placa de Crecimiento/citología , Humanos , Ratones , Mutación/genética
19.
J Vet Intern Med ; 38(1): 258-267, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-37916855

RESUMEN

BACKGROUND: Fibrocartilaginous embolic myelopathy (FCE) is a well-documented condition in dogs although rarely reported in chondrodystrophic breeds. Genetic associations have not been defined. OBJECTIVES: Define the association of the chondrodystrophy-associated FGF4L2 retrogene with histopathologically confirmed cases of FCE. ANIMALS: Ninety-eight dogs with a histopathologic diagnosis of FCE. METHODS: Retrospective multicenter study. Dogs were genotyped for the FGF4L2 and FGF4L1 retrogenes using DNA extracted from formalin-fixed, paraffin-embedded tissue. Associations between breed, FCE and retrogene status were investigated with reference to a hospital population and known breed and general population allele frequencies. RESULTS: FGF4L2 genotype was defined in 89 FCE cases. Fibrocartilaginous embolic myelopathy was present in 22 dogs from FGF4L2-segregating breeds with allele frequencies of ≥5%; however, all dogs were wild type. Two Labrador retrievers with FCE carried FGF4L2 alleles. Frequency of the FGF4L2 allele was significantly (P < .001) and negatively associated with FCE relative to predicted hospital-population dogs. FCE was overrepresented in Boxer, Great Dane, Yorkshire Terrier, Bernese Mountain Dog, Miniature Schnauzer, Rottweiler, and Shetland Sheepdog breeds. CONCLUSIONS AND CLINICAL IMPORTANCE: Study data based on genotypically and histopathologically defined cases support the historical observation that FCE is uncommon in chondrodystrophic dog breeds. FGF4 plays an important role in angiogenesis and vascular integrity; anatomical studies comparing chondrodystrophic and non-chondrodystrophic dogs might provide insight into the pathogenesis of FCE.


Asunto(s)
Enfermedades de los Cartílagos , Enfermedades de los Perros , Embolia , Enfermedades de la Médula Espinal , Animales , Perros , Enfermedades de los Cartílagos/genética , Enfermedades de los Cartílagos/veterinaria , Enfermedades de los Cartílagos/complicaciones , Enfermedades de los Perros/diagnóstico , Genotipo , Enfermedades de la Médula Espinal/genética , Enfermedades de la Médula Espinal/veterinaria
20.
J Cell Mol Med ; 17(12): 1515-24, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24373548

RESUMEN

Cartilage has limited repair and regeneration capacity, thus damage of cartilage often results in its dysfunction and even chronic diseases like osteoarthritis (OA). Chondrogenesis induced by tissue-engineering methods is essential to treating cartilage-related diseases. MicroRNAs (miRNAs) are a class of small non-coding single-stranded RNAs which exert their biological effects by binding to the target messenger RNAs (mRNAs), resulting in decay or translation suppression of target mRNAs. There are emerging evidence indicating that miRNAs may play important roles in regulating both prenatal and postnatal chondrogenesis. During embryonic skeletal development, prenatal chondrogenesis is thought to be a precondition for formation of cartilage in developing limbs. Plenty of studies on different types of stem cells have undoubtedly proven their capacity of differentiating into chondrocytes. MiRNAs are found to comprehensively modulate these processes by establishing an interaction network with target genes, transcription factors and cytokines et al. In addition, translational application of miRNA technology has also been explored. In this review, we focus on the up-dated progress on regulatory mechanisms of miRNAs in prenatal and postnatal chondrogenesis. In addition, several miRNA target genes and roles of miRNAs in cartilage-related diseases are also discussed. This will contribute to studies of chondrogenesis mechanisms and development of new treating methods.


Asunto(s)
Enfermedades de los Cartílagos/genética , Cartílago/embriología , Cartílago/crecimiento & desarrollo , Condrogénesis/genética , MicroARNs/metabolismo , Animales , Cartílago/metabolismo , Diferenciación Celular , Humanos , MicroARNs/genética , Células Madre/citología , Células Madre/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA